Bortezomib for Treating Glomerular Diseases

Inclusion Criteria: * Glomerular diseases confirmed by renal biopsy (including IgA nephropathy, membranous nephropathy, FSGS, etc.) * Aged 18-65, male or female * Signed informed consent * 24h proteinuria \>1.5g/24h * Glomerular filtration rate (eGFR) \>30ml/min/1.73m2 (calculated according to CKD-EPI formula) within 14 days before enrollment. * Blood pressure \<140/90mmHg after drug treatment * Unless there are contraindications, subjects must take a steady dose of ACEI and/or ARB for at least 4 weeks before screening Exclusion Criteria: * Renal pathology: glomerulosclerosis ratio \>70%, interstitial fibrosis \> severe * Received immunosuppressant treatment within the past 6 months * Inability to tolerate bortezomib * Platelet count \< 30×109/L within 14 days before enrollment * Neutrophil count \< 1.0×109/L within 14 days before enrollment * Subjects had \>grade 2 peripheral neuropathy within 14 days before enrollment * ECG evidence of myocardial infarction or NYHA Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmia, or acute ischemia or active conduction system abnormalities within 6 months before enrollment * Abnormal liver function such as alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) \>=3 times normal upper limit (ULN), total bilirubin \>= 2 times ULN * Newly diagnosed malignant tumor (within 5 years) or undergoing radiotherapy/chemotherapy * Women who are pregnant or breast-feeding, or women of childbearing age who cannot guarantee effective contraception * New serious life-threatening infections * Active infectious diseases such as active tuberculosis, active viral hepatitis, HIV infection. * Mental disorders and psychotropic drug uses * Patients with an estimated life expectancy of fewer than 12 months * Patients that were difficult to follow up on or had poor compliance * Patients who do not wish to sign the form of informed consent